Myriad Publications: Scientific Presentations

Poster presentations and other publications with Myriad authorship,

Click HERE to view peer-reviewed scientific journals.

Myriad's family of products

  • Identifies risk of developing 11 hereditary cancers

  • Identifies risk of breast cancer recurrence to inform treatment strategies

  • Identifies BRCA1/2 mutations to inform treatment strategies

  • Identifies HRD status to inform treatment strategies

  • Identifies prostate cancer aggressiveness to inform treatment strategies

  • Identifies at-risk couples for a pregnancy affected by inherited conditions

  • Identifies risk of chromosomal conditions for expectant parents

  • Identifies how genes affect outcomes with certain mental health medications

Previous Test
    Next Test

    © 2022 Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad MyRisk Hereditary Cancer, the Myriad MyRisk Hereditary Cancer logo, BRACAnalysis, the BRACAnalysis logo, Prolaris, the Prolaris logo, Foresight, the Foresight logo, GeneSight, the GeneSight logo, MyChoice, MyChoice logo, Endopredict, the Endopredict logo, Prequel, the Prequel logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.